Nuro Health raises £12M Series A extension for ADHD EEG platform NHS pilot scale-up
Summary
London-based Nuro Health secured a £12M Series A extension from Octopus Ventures and new investor Balderton Capital to scale their EEG neurofeedback ADHD platform following positive 800-child schools pilot results. The extension funds expansion to 200 schools, development of a parent-facing home practice app, and initiation of a formal NHS health technology assessment submission.
Why it matters
Balderton Capital joining at Series A extension stage signals Nuro Health has demonstrated product-market fit beyond what typical seed-stage investors require for follow-on. NHS HTA submission is the critical reimbursement pathway — if successful, it would make Nuro Health's ADHD platform standard of care for non-pharmacological treatment in UK children.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial